- Sarepta (SRPT) rallies 6% AH.
- The company is out with data through week 120 in the Phase 2b eteplirsen extension study.
- Summary: Patients in 30mg and 50mg cohorts able to perform the 6-minute walk test "experienced a decline of 13.9 meters, or less than 5%, from baseline in walking ability;" treatment benefit is a statistically significant 64.9 meters.
- SRPT says it "now [has] more than two years of data with eteplirsen on the 6-minute walk test, the most accepted clinical outcome measure in DMD which demonstrates walking stability that [the company] believes would not be expected based on the natural history of this disease over the same time period." (PR)
From other sites
Sarepta Therapeutics : Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developmentsat 4-traders.com (Mar 24, 2015)
at Benzinga.com (Jan 15, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 13, 2015)
at Benzinga.com (Jan 12, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs